KCNH2 polymorphism and methadone dosage interact to enhance QT duration.

[1]  P. Mehler,et al.  QTc interval screening in an opioid treatment program. , 2013, The American journal of cardiology.

[2]  C. Mcgorrian,et al.  Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy. , 2012, Addiction.

[3]  J. Strang,et al.  Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation? , 2011, Drug and alcohol review.

[4]  M. Trudeau,et al.  hERG potassium channel gating is mediated by N- and C-terminal region interactions , 2011, The Journal of general physiology.

[5]  J. Bell,et al.  Estimating the risk of fatal arrhythmia in patients in methadone maintenance treatment for heroin addiction. , 2011, Drug and alcohol review.

[6]  T. Clausen,et al.  Opioid maintenance patients with QTc prolongation: congenital long QT syndrome mutation may be a contributing risk factor. , 2010, Drug and alcohol dependence.

[7]  C. Eap,et al.  Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. , 2010, Archives of internal medicine.

[8]  L. Peltonen,et al.  Common Candidate Gene Variants Are Associated with Qt Interval Duration in the General Population from The , 2022 .

[9]  H. Kleber.  Methadone maintenance 4 decades later: thousands of lives saved but still controversial. , 2008, JAMA.

[10]  T. Spector,et al.  Heritability of QT Interval: How Much Is Explained by Genes for Resting Heart Rate? , 2008, Journal of cardiovascular electrophysiology.

[11]  G. Bigelow,et al.  QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. , 2007, Archives of internal medicine.

[12]  D. Levy,et al.  Common Genetic Variation in KCNH2 Is Associated With QT Interval Duration: The Framingham Heart Study , 2007, Circulation.

[13]  L. Tiret,et al.  Confirmation of associations between ion channel gene SNPs and QTc interval duration in healthy subjects , 2007, European Journal of Human Genetics.

[14]  M. Connock,et al.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. , 2007, Health technology assessment.

[15]  D. Shah,et al.  Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. , 2006, Archives of internal medicine.

[16]  Beverley Balkau,et al.  Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population , 2005, European Journal of Human Genetics.

[17]  R. Judson,et al.  Allelic dropout in long QT syndrome genetic testing: a possible mechanism underlying false-negative results. , 2005, Heart rhythm.

[18]  Bridget A. Martell,et al.  Impact of methadone treatment on cardiac repolarization and conduction in opioid users. , 2005, The American journal of cardiology.

[19]  Michael C Sanguinetti,et al.  Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.

[20]  P. Mehler,et al.  Cocaine-Related Torsade de Pointes in a Methadone Maintenance Patient , 2005, Journal of addictive diseases.

[21]  G. Perugi,et al.  QTc Interval Prolongation in Patients on Long-Term Methadone Maintenance Therapy , 2004, European Addiction Research.

[22]  J. Brugada,et al.  Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG , 2003, Circulation.

[23]  F. Segura,et al.  QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. , 2003, The American journal of cardiology.

[24]  Jason M. White,et al.  Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. , 2003, Drug and alcohol dependence.

[25]  Evan Mokwe,et al.  Torsade de pointes due to methadone. , 2003, Annals of internal medicine.

[26]  J. Erdmann,et al.  A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. , 2003, Cardiovascular research.

[27]  Robert M Califf,et al.  What clinicians should know about the QT interval. , 2003, JAMA.

[28]  A. Katchman,et al.  Influence of Opioid Agonists on Cardiac HumanEther-a-go-go-related Gene K+ Currents , 2002, Journal of Pharmacology and Experimental Therapeutics.

[29]  P. Mehler,et al.  Torsade de Pointes Associated with Very-High-Dose Methadone , 2002, Annals of Internal Medicine.

[30]  A. Moss,et al.  The Long-QT Syndrome , 1992 .

[31]  E. Selker.  Gene silencing: repeats that count. , 1999 .

[32]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[33]  E. Donoso,et al.  The effect of heroin and multiple drug abuse on the electrocardiogram. , 1973, American heart journal.

[34]  R. Judson,et al.  Pharmacogenetic Issues in Thorough QT Trials , 2012, Molecular Diagnosis & Therapy.

[35]  Odd Hordvin,et al.  The Drug Situation in Norway 2011 : Annual report to the European Monitoring Centre for Drugs and Drug Addiction - EMCDDA , 2009 .